长春瑞滨联合卡培他滨治疗晚期乳腺癌的临床研究  

Clinical Study of Vinorelbine Combined with Capecitabine for Advanced Metastatic Breast Cancer

作　　者：徐绮腻[1] 陈蕾[1] 郑瑾[1] 

机构地区：[1]汕头大学医学院附属肿瘤医院内科,515031

出　　处：《实用癌症杂志》2013年第6期645-648,共4页The Practical Journal of Cancer

摘　　要：目的观察长春瑞滨(vinorelbine,NVB)联合卡培他滨(capecitabine,CAPE)对蒽环和(或)紫杉类耐药的晚期乳腺癌的疗效及毒性。方法蒽环和(或)紫杉类耐药晚期乳腺癌患者29例,给予长春瑞滨25 mg/m2,第1、8 d,采用PICC管静脉滴注;卡培他滨每天1000 mg/m2,每天2次,餐后30 min用温水送服,连用14 d,休息7 d,21 d为1个周期。2个周期后评价疗效,有效者化疗4个周期以上。随访6～30个月。结果 29例患者共化疗124个周期,化疗周期中位数为4个周期(2～10个周期),完全缓解(CR)1例,部分缓解(PR)13例,占44.8%,稳定(SD)10例,占34.5%,进展(PD)5例,占17.2%。有效率(CR+PR)达48.3%。中位疾病进展时间(TTP)为5.2个月,中位总生存期(OS)为18.2个月。常见不良反应为骨髓抑制、胃肠道反应和手足综合征等。结论长春瑞滨联合卡培他滨对紫杉类或蒽环类耐药的晚期乳腺癌有较好的疗效,毒性可以耐受。Objective To observe the efficiency and toxicities of vinorelbine （NVB） combined with capecitabine （CAPE） for advanced breast cancer resistant to anthracycline or taxol treatment. Methods 29 cases of advanced breast cancer patients who were resistant to anthracycline or taxol treatment received NVB ＋ CAPE regimen,infusion of vinorelbine 25 mg/m2 by PICC on day 1 and day 8 ,and capecitabine 1000 mg/m2 orally 30 min after meal twice a day for 14 days. 21 days was a cycle for both groups. The efficacy was evaluated after 2 cycles, and the effective patients received more than 4 cycles. The follow-up was 6 - 30 months. Results In total, 124 cycles were finished by 29 patients. The median number of treatment was d cycles （2 - 10 cycles ）. There was 1 case of complete remission, 13 partial remission （ 44.8 % ） , 10 stable disease （ 34.5 % ）, 5 progression disease（ 17.2% ）. The overall response rate（ CR ＋ PR） was 48.3%. The median time to progression was 5.2 months,the median overall survival was 18.2 months. The predominant toxicities were myelosuppression, gastrointestinal reaction and hand-foot syndrome,etc. Conclusion Combination therapy of vinorelbine and capecitabine is effective with tolerable toxicities for advanced breast cancer patients with refractory and relapsed afteranthracycline or taxol treatment.

关 键 词：乳腺肿瘤 长春瑞滨 卡培他滨 化学治疗 不良反应 

分 类 号：R737.9[医药卫生—肿瘤]